BRAZILIAN CONSENSUS ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN PEDIATRIC PATIENTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB)
- PMID: 36995890
- DOI: 10.1590/S0004-2803.2022005S1-04
BRAZILIAN CONSENSUS ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN PEDIATRIC PATIENTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB)
Abstract
Background: Approximately 25% of patients with inflammatory bowel disease (IBD) develop the disease during childhood or adolescence and treatment aims to control active symptoms and prevent long-term complications. The management of Crohn's disease (CD) and ulcerative colitis (UC) can be especially challenging in children and adolescents, related to particularities that may affect growth, development, and puberty.
Objective: This consensus aims to provide guidance on the most effective medical and surgical management of pediatric patients with CD or UC.
Methods: Experts in Pediatric IBD representing Brazilian gastroenterologists (Brazilian Organization for Crohn's Disease and Colitis [GEDIIB]) developed this consensus. A rapid review was performed to support the recommendations/statements. Medical and surgical recommendations were structured and mapped according to the disease type, disease activity, and indications and contraindications for medical and surgical treatment. After structuring the statements, the modified Delphi Panel methodology was used to conduct the voting. The process took place in three rounds: two using a personalized and anonymous online voting platform and one face-to-face. Whenever participants did not agree with a specific recommendation, an option to explain why was offered to enable free-text responses and provide the opportunity for the experts to elaborate or explain disagreement. The consensus of recommendations in each round was accepted when reached ≥80% agreement.
Results and conclusion: The recommendations are presented according to the stage of treatment and severity of the disease in three domains: management and treatment (drug and surgical interventions), criteria for evaluating the effectiveness of medical treatment, and follow-up/ patient monitoring after initial treatment, follow-up/ patient monitoring after initial treatment. Surgical recommendations were grouped according to disease type and recommended surgery. The target audience for this consensus was general practitioners, gastroenterologists, and surgeons interested in the treatment and management of pediatric CD and UC. Additionally, the consensus aimed to support the decision-making of health insurance companies, regulatory agencies, and health institutional leaders and/or administrators.
Similar articles
-
SURGICAL MANAGEMENT OF ADULT CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS: A CONSENSUS FROM THE BRAZILIAN ORGANIZATION OF CROHN'S DISEASE AND COLITIS (GEDIIB).Arq Gastroenterol. 2023 Mar 24;59(suppl 1):1-19. doi: 10.1590/S0004-2803.2022005S1-01. eCollection 2023. Arq Gastroenterol. 2023. PMID: 36995887
-
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF ULCERATIVE COLITIS IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).Arq Gastroenterol. 2023 Mar 24;59(suppl 1):51-84. doi: 10.1590/S0004-2803.2022005S1-03. eCollection 2023. Arq Gastroenterol. 2023. PMID: 36995889
-
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).Arq Gastroenterol. 2023 Mar 24;59(suppl 1):20-50. doi: 10.1590/S0004-2803.2022005S1-02. eCollection 2023. Arq Gastroenterol. 2023. PMID: 36995888
-
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3. J Pediatr Gastroenterol Nutr. 2007. PMID: 17460505
-
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.Sci Rep. 2024 Feb 21;14(1):4314. doi: 10.1038/s41598-024-54332-1. Sci Rep. 2024. PMID: 38383742 Free PMC article.
Cited by
-
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years.Pharmaceuticals (Basel). 2023 Sep 8;16(9):1272. doi: 10.3390/ph16091272. Pharmaceuticals (Basel). 2023. PMID: 37765080 Free PMC article. Review.
-
Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review.Int J Mol Sci. 2024 Feb 8;25(4):2077. doi: 10.3390/ijms25042077. Int J Mol Sci. 2024. PMID: 38396754 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical